17th Annual Corporate Profiles
Click on any logo below to be directed to Corporate Profiles prepared by leading companies in the clinical trials industry. We hope you find this resource most useful and informative.
ACM Globalwww.acmgloballab.com
Actigraphwww.theactigraph.com
Advanced Clinicalwww.advancedclinical.com
Almacwww.almacgroup.com
Andersonhttp://www.andersonpackaging.com
Aptiv Solutionswww.aptivsolutions.com
Asamanwww.asaman.com
AtCorwww.atcormedical.com
Barnettwww.barnettinternational.com/
Bioclinicawww.bioclinica.com/
Biomedical Systems www.biomedsys.com
Catalent Pharma Solutions www.catalent.com
Clinical Financial Serviceswww.clinicalfinancialservices.com/
Clinical Resource Networkwww.clinicalresource.net/
Comprehensive Clinical Developmentwww.comprehensivecd.com/
Corporate Translationscorptransinc.com
Crucialwww.clsds.com/
DaVita Clinical Researchwww.davitaclinicalresearch.com
ERTwww.ert.com
Ethical & Independent Review Serviceswww.eandireview.com
Eurofinswww.eurofins.com/en.aspx
Evaluate Pharmawww.evaluatepharma.com
Exco InTouch Ltdwww.excointouch.com
ExecuPharm, Inc.www.execupharm.com/
ExL Pharmawww.exlpharma.com/
Firecrestwww.firecrestclinical.com/
Global Care Clinical Trialsglobalcarect.com/
Markenwww.marken.com
Medical Research Network (MRN)www.themrn.co.uk/
Medpacewww.medpace.com
Octagonwww.octagonresearch.com/
Outcomewww.outcome.com/
PAREXEL International www.PAREXEL.com
PCM Trialswww.pcmtrials.com/
Perceptive Informatics www.perceptive.com
PharmaNetwww.pharmanet.com
PPDwww.ppdi.com
PRA International www.prainternational.com
REGISTRAT-MAPIwww.REGISTRAT-MAPI.com
SASwww.sas.com/
Sparta Systems Inc.www.spartasystems.com/
Spectra Clinical Research www.spectraclinicalresearch.com
Vetter Pharma Internationalwww.vetter-pharma.com/
Worldwide Clinical Trialswww.wwctrials.com/
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.